# Developmental Therapeutics

> **NIH NIH P30** · UNIVERSITY OF WISCONSIN-MADISON · 2024 · $140,755

## Abstract

UWCCC DEVELOPMENTAL THERAPEUTICS (DT) PROGRAM
Co-leaders: Christian Capitini, Beth Weaver, and Dustin Deming
PROJECT SUMMARY/ABSTRACT
The discovery, development, and translation of new biomarkers and therapeutics are critical to improve the
clinical outcomes for patients with cancer in our catchment area and beyond. The mission of the UW Carbone
Cancer Center (UWCCC) Developmental Therapeutics (DT) Program is to improve cancer patient outcomes
by discovering new targets, developing new therapies and biomarkers, and translating preclinical research into
phase I-III clinical trials. The DT Program provides translational direction not only for DT members, but also for
the basic science programs within the UWCCC, including GEM, VR, and TM. Our community influenced bench-
to-bedside and bedside-to-bench research enables a greater understanding of mechanisms of response and
resistance which enable the discovery and development of new drugs, biomarkers, and therapeutic strategies.
The DT Program has 56 core members, representing 20 departments and 5 different schools/colleges. Research
impacts of DT members are evidenced by research awards totaling $20.8M in annual direct cost of peer-reviewed
and non-peer reviewed funding (including $5.41M NCI, $5.06M cancer-related other NIH agencies, $3.25M peer-
reviewed non-NIH sources, $7.05M non-peer reviewed funding) and a significant number of publications (1,011
publications, 12% of which result from intra-programmatic collaboration, 31% from inter-programmatic work and
55% from inter-institutional work). Of note, 29% were publications in high impact journals (impact factor > 10).
The thematic aims of the DT program are to: 1) discover and develop combination immunotherapy approaches
that bridge innate and adaptive immunity for treatment of advanced cancers; 2) discover and develop new drug
molecular targets, precision medicine therapies, and biomarkers; and 3) translate new immunotherapeutic
approaches and precision medicine therapies to clinical trials, including phase I-III studies. To address these
aims, members of the DT Program come from basic science, applied science, and clinical departments. This
program has expertise in therapeutic discovery and development across immunotherapy/cell therapy and
precision medicine therapies. Additionally, translational and clinical research DT program members apply intra-
and inter-programmatic research discoveries in clinical trials. DT members are performing the majority of
investigator-initiated early phase studies and advance UWCCC science into phase II and III clinical trials with an
emphasis on diseases that are high priority for our catchment area, including breast cancer, lymphoma/myeloma,
prostate, and head and neck cancers. Finally, the DT program is dedicated to the mentorship of junior
investigators as part of formalized training programs, and also through DT-led meetings, pilot grants, and
mentorship from the DT leadership.

## Key facts

- **NIH application ID:** 10873023
- **Project number:** 5P30CA014520-50
- **Recipient organization:** UNIVERSITY OF WISCONSIN-MADISON
- **Principal Investigator:** Dustin A Deming
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $140,755
- **Award type:** 5
- **Project period:** 1997-04-25 → 2028-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10873023

## Citation

> US National Institutes of Health, RePORTER application 10873023, Developmental Therapeutics (5P30CA014520-50). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10873023. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*